RxDoctor Payments Data

Bruna Arrunategui-Rodriguez, MD

Internal Medicine · Highland, INNPI 1992979215

Payments from drug & device makers

$999in general payments, 2019–2025

Across 14 payments — averaging $71.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$470
  • Intuitive Surgical$240
  • Travere Therapeutics, Inc.$193
  • Novo Nordisk$29
  • Lilly USA, LLC$20
  • GSK$19
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$999100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$999 in reported general payments places this provider in the 75th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$240,104
Medicare patients
356
Services billed
3,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$61,157
MounjaroTirzepatide46$54,975
EliquisApixaban70$47,497
JardianceEmpagliflozin29$32,831
TradjentaLinagliptin24$25,075
JanuviaSitagliptin Phosphate22$25,006
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$14,996
FarxigaDapagliflozin Propanediol20$14,494
XareltoRivaroxaban11$13,370
EntrestoSacubitril/Valsartan12$8,232
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$8,173
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$4,912
Breo ElliptaFluticasone/Vilanterol12$4,711
Humalog Kwikpen U-100Insulin Lispro21$3,160
Novolog FlexpenInsulin Aspart22$3,117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$29$61,15750 claims
Lilly USA, LLCMounjaro$20$54,97546 claims
PfizerEliquis$16$47,49770 claims
AstraZenecaFarxiga$470$14,49420 claims
GSKBreo Ellipta$19$4,71112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Highland

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →